JP6047160B2 - 天然ａｈｒリガンド依存性癌を治療および／または予防するための手段および方法 - Google Patents

天然ａｈｒリガンド依存性癌を治療および／または予防するための手段および方法 Download PDF

Info

Publication number
JP6047160B2
JP6047160B2 JP2014528990A JP2014528990A JP6047160B2 JP 6047160 B2 JP6047160 B2 JP 6047160B2 JP 2014528990 A JP2014528990 A JP 2014528990A JP 2014528990 A JP2014528990 A JP 2014528990A JP 6047160 B2 JP6047160 B2 JP 6047160B2
Authority
JP
Japan
Prior art keywords
ahr
cancer
tdo
pharmaceutical composition
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014528990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014526450A (ja
JP2014526450A5 (https=
Inventor
プラッテン，ミヒャエル
オピッツ，クリスティアーネ
ヴィック，ヴォルフガング
リッツェンブルガー，ウルリケ
Original Assignee
ドイチェス クレブスフォルシュンクスツェントルム
ドイチェス クレブスフォルシュンクスツェントルム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドイチェス クレブスフォルシュンクスツェントルム, ドイチェス クレブスフォルシュンクスツェントルム filed Critical ドイチェス クレブスフォルシュンクスツェントルム
Publication of JP2014526450A publication Critical patent/JP2014526450A/ja
Publication of JP2014526450A5 publication Critical patent/JP2014526450A5/ja
Application granted granted Critical
Publication of JP6047160B2 publication Critical patent/JP6047160B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11011—Tryptophan 2,3-dioxygenase (1.13.11.11), i.e. indolamine 2,3-dioxygenase 2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11017—Indole 2,3-dioxygenase (1.13.11.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014528990A 2011-09-07 2012-09-07 天然ａｈｒリガンド依存性癌を治療および／または予防するための手段および方法 Active JP6047160B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161531861P 2011-09-07 2011-09-07
US61/531,861 2011-09-07
PCT/EP2012/067504 WO2013034685A1 (en) 2011-09-07 2012-09-07 Means and methods for treating and/or preventing natural ahr ligand-dependent cancer

Publications (3)

Publication Number Publication Date
JP2014526450A JP2014526450A (ja) 2014-10-06
JP2014526450A5 JP2014526450A5 (https=) 2015-08-06
JP6047160B2 true JP6047160B2 (ja) 2016-12-21

Family

ID=46832380

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528990A Active JP6047160B2 (ja) 2011-09-07 2012-09-07 天然ａｈｒリガンド依存性癌を治療および／または予防するための手段および方法

Country Status (15)

Country Link
US (1) US9593062B2 (https=)
EP (1) EP2753315B1 (https=)
JP (1) JP6047160B2 (https=)
KR (1) KR20140074330A (https=)
CN (1) CN104023713A (https=)
AU (1) AU2012306285B2 (https=)
BR (1) BR112014004937A2 (https=)
CA (1) CA2846275C (https=)
ES (1) ES2626015T3 (https=)
HK (1) HK1201471A1 (https=)
IL (1) IL231107A (https=)
MX (1) MX348941B (https=)
RU (1) RU2640913C2 (https=)
WO (1) WO2013034685A1 (https=)
ZA (1) ZA201401011B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2953065B2 (ja) 1990-12-28 1999-09-27 石川島播磨重工業株式会社 宇宙飛翔体

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102271498B1 (ko) * 2013-08-30 2021-07-05 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 종양 치료를 위한 키누레닌 고갈 효소의 투여
JP7080053B2 (ja) 2014-08-29 2022-06-03 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
CA2980730A1 (en) 2015-03-23 2016-09-29 The Brigham And Women's Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
US11542486B2 (en) 2016-03-02 2023-01-03 Board Of Regents, The University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
CN107510694B (zh) * 2016-06-16 2022-03-29 中国科学院上海巴斯德研究所 激活潜伏感染的艾滋病病毒的化合物及其在艾滋病治疗中的应用
CN106214673A (zh) * 2016-08-31 2016-12-14 深圳市第二人民医院 表没食子儿茶素没食子酸酯在制备预防或治疗膀胱肿瘤的药物中的用途
WO2018085775A1 (en) * 2016-11-04 2018-05-11 Ohio State Innovation Foundation Methods and compositions for treating multiple myeloma and increasing antibody dependent cell cytotoxicity by targeting the aryl hydrocarbon receptor
WO2019036657A1 (en) * 2017-08-17 2019-02-21 Kyn Therapeutics AHR INHIBITORS AND USES THEREOF
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CA3096549A1 (en) 2018-04-16 2019-10-24 Board Of Regents, The University Of Texas System Human kynureninase enzymes and uses thereof
RU2699932C1 (ru) * 2018-11-14 2019-09-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ прогнозирования риска развития рака печени у экспериментальных животных
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
KR20220125323A (ko) * 2020-01-10 2022-09-14 이케나 온콜로지, 인코포레이티드 Ahr 억제제 및 이의 용도
CN112807305A (zh) * 2020-12-31 2021-05-18 中国科学院生态环境研究中心 Ch223191在抑制肿瘤细胞迁移中的应用
CN114019164B (zh) * 2020-12-31 2023-11-21 中国科学院生态环境研究中心 筛选抗胶质瘤药物的方法和试剂盒
CN114470238A (zh) * 2022-03-25 2022-05-13 华中科技大学同济医学院附属协和医院 AhR抑制剂CH223191在制备抑制肿瘤相关巨噬细胞药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
JP4587652B2 (ja) 2002-09-09 2010-11-24 株式会社フラバミン 新規フラボノイド化合物及びその利用
US20060135445A1 (en) * 2003-02-04 2006-06-22 Kabushiki Kaisha Yakult Honsha Breast cancer-resistant protein inhibitor
ES2421191T3 (es) * 2006-05-03 2013-08-29 Symrise Ag Antagonistas del receptor de Ah
US20110159017A1 (en) 2008-04-11 2011-06-30 Ludwig Institute For Cancer Research Ltd. Trytophan catabolism in cancer treatment and diagnosis
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2953065B2 (ja) 1990-12-28 1999-09-27 石川島播磨重工業株式会社 宇宙飛翔体

Also Published As

Publication number Publication date
BR112014004937A2 (pt) 2017-06-20
ES2626015T3 (es) 2017-07-21
CA2846275C (en) 2019-07-16
CN104023713A (zh) 2014-09-03
KR20140074330A (ko) 2014-06-17
EP2753315B1 (en) 2017-03-01
MX2014002776A (es) 2014-11-25
US20140294860A1 (en) 2014-10-02
JP2014526450A (ja) 2014-10-06
MX348941B (es) 2017-07-04
AU2012306285B2 (en) 2017-05-18
EP2753315A1 (en) 2014-07-16
CA2846275A1 (en) 2013-03-14
WO2013034685A1 (en) 2013-03-14
US9593062B2 (en) 2017-03-14
IL231107A (en) 2017-11-30
AU2012306285A1 (en) 2014-02-27
ZA201401011B (en) 2018-07-25
IL231107A0 (en) 2014-04-30
RU2640913C2 (ru) 2018-01-12
RU2014104696A (ru) 2015-10-20
HK1201471A1 (en) 2015-09-04

Similar Documents

Publication Publication Date Title
JP6047160B2 (ja) 天然ａｈｒリガンド依存性癌を治療および／または予防するための手段および方法
Guan et al. Tumor‐associated macrophages promote prostate cancer progression via exosome‐mediated miR‐95 transfer
Lin et al. Chemokine C‐C motif receptor 5 and C‐C motif ligand 5 promote cancer cell migration under hypoxia
JP5651331B2 (ja) 結腸直腸癌の治療におけるプロガストリン阻害剤
Pang et al. Pancreatic cancer-derived exosomal microRNA-19a induces β-cell dysfunction by targeting ADCY1 and EPAC2
AU2016369407A1 (en) Treatment of fibrosis
JP7514846B2 (ja) 肝毒性の治療
Xiao et al. IL‐17A promotes lung fibrosis through impairing mitochondrial homeostasis in type II alveolar epithelial cells
Wei et al. Signal Peptide Peptidase, Encoded by HM 13, Contributes to Tumor Progression by Affecting EGFR v III Secretion Profiles in Glioblastoma
Zhu et al. miR‐98‐5p alleviated epithelial‐to‐mesenchymal transition and renal fibrosis via targeting Hmga2 in diabetic nephropathy
WO2013153092A1 (en) Inhibitors of receptor for advanced glycation-end products (rage) for use in treating and/or preventing inflammation- and/or damage-induced cancer
He et al. Identification of novel biomarker hsa_circ_0003914 for rheumatoid arthritis from plasma exosomes
Xu et al. Bisphenols exposure at environmentally relevant dose promoted ovarian cancer progression and modulated tumor microenvironment through β-catenin/SPP1 axis
Shi et al. Tumor-immune-neural circuit disrupts energy homeostasis in cancer cachexia
Qian et al. PFOA exposure promotes prostate cancer progression by enhancing autophagy through m6A modification of MAPK15 mRNA
US20250179502A1 (en) Targeting neuropilin 2 (nrp2) in lethal prostate cancer
Liu et al. The circular RNA circGlis3 protects against islet β-cell dysfunction and apoptosis during obesity
Lv et al. The Fusion Circular RNA F-circEA1 Promotes Non-small Cell Lung Carcinoma Progression through ALK Downstream Signaling
Wang et al. A positive feedback loop between TAZ and miR-942-3p modulates proliferation, migration, epithelial-mesenchymal transition process and glycometabolism in human bladder cancer
Xu et al. Bufalin suppresses tumour microenvironment-mediated angiogenesis by inhibiting the STAT3 signaling pathway
Guo et al. UBE2C Directly Targeted by mirR-548-5p Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein ZEB1/2 in NSCLC
Shi et al. LncRNA GLTC targets LDHA for succinylation and enzyme activity to promote differentiated thyroid cancer progression and radioiodine resistance
Li et al. A specific Upregulated lncRNA in Colorectal Cancer Promotes Cancer Progression by Modulating miR-185-5p/CCND2 Axis
Yao et al. IL‐17 Promotes the Phenotypic Transformation of Vascular Smooth Muscle Cells Through PI3K/AKT Signaling Pathway
Wang et al. Overexpression of SMYD3 contributes to sorafenib resistance by epigenetically activating the expression of multiple cancer-promoting genes in hepatocellular carcinoma

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20141010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161118

R150 Certificate of patent or registration of utility model

Ref document number: 6047160

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250